Trump's Proposed 100% Pharma Tariff Sparks Alarm, But Indian Drugmakers Seen Shielded: Jefferies

Former President Donald Trump's suggestion of a 100% tariff on pharmaceutical imports has ignited widespread concern across the global healthcare sector. The proposal, part of a broader trade agenda, targets the U.S. drug supply chain, which heavily relies on lower-cost generic medications. While the announcement rattled markets, investment bank Jefferies offered a mitigating perspective, stating that Indian generic drug manufacturers are likely to remain largely unaffected. Analysts noted that Indian pharma firms already comply with stringent U.S. FDA regulations and benefit from the U.S.-India Trade Policy Forum, which may provide exemptions or carve-outs from such blanket tariffs. This distinction is crucial, as Indian companies supply over 40% of generic drugs consumed in the United States. The tariff threat, if enacted, would primarily impact branded biologics and certain specialty drugs, rather than the high-volume, low-cost generics that form the backbone of India's pharmaceutical exports.